Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
23.90
+0.65 (2.79%)
Oct 19, 2026, 3:04 PM EDT - Market open
Neurogene Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
131
Market Cap
478.26M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 925.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Arvinas | 316.70M |
| REGENXBIO | 174.48M |
| CytomX Therapeutics | 18.30M |
| Aclaris Therapeutics | 8.22M |
| Allogene Therapeutics | 4.64M |
| Oculis Holding AG | 1.45M |
| Entera Bio | 42.00K |
NGNE News
- 11 days ago - Neurogene initiated with an Overweight at JPMorgan - TheFly
- 13 days ago - Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Neurogene Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 5 weeks ago - Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference - Business Wire
- 2 months ago - Neurogene price target lowered to $65 from $70 at H.C. Wainwright - TheFly
- 2 months ago - Neurogene price target raised to $81 from $69 at Guggenheim - TheFly
- 2 months ago - Neurogene price target lowered to $166 from $180 at Canaccord - TheFly
- 2 months ago - Neurogene Slides: Corporate presentation - Filings